July 1, 2010 – AAA has signed an agreement with the Institut Curie to build, install and operate a pharmaceutical laboratory for radiopharmaceuticals production at the Institut Curie’s René Huguenin specialist cancer hospital in Saint-Cloud, Paris.
The cyclotron will guarantee the supply of high quality radiopharmaceuticals for the hospital’s two PET (Positron Emission Tomography) scanners, which are increasingly used in the diagnosis and treatment of cancers, enabling clinicians to track the progress of treatments such as chemotherapy as well as the appearance of secondary tumors and metastases.
René Huguenin is AAA’s fifth production center in France. It will allow AAA to supply other hospitals in western France. The new cyclotron is expected to be fully operational in 2013.
This partnership provides an exciting opportunity for both organizations to develop new and innovative oncology markers, and to offer the most up to date, innovative and targeted imaging techniques to patients. There is a growing need for better oncology treatments and AAA is committed to developing innovative diagnostics and therapeutics. This collaboration agreement with the Institut Curie will significantly strengthen AAA’s position in this market and reinforce René Huguenin Hospital’s leadership in the field of nuclear medicine.
For more details and highlights please refer to the official press releases and press articles posted in the “press room” section.